Watchlist Price Alert

Seres Therapeutics Inc. (MCRB)

NASDAQ: MCRB · Real-Time Price · USD

7.00

0.00 (0.00%)

At close: Jun 03, 2025, 3:59 PM

7.31

4.43%

After-hours: Jun 03, 2025, 06:06 PM EDT

0.00% (1D)

Bid	6.7
Market Cap	61.13M
Revenue (ttm)	n/a
Net Income (ttm)	72.95M
EPS (ttm)	-7.95
PE Ratio (ttm)	-0.88
Forward PE	-0.87
Analyst	Hold

Ask	7.52
Volume	127,977
Avg. Volume (20D)	89,496
Open	7.10
Previous Close	7.00
Day's Range	6.98 - 7.41
52-Week Range	6.53 - 30.60
Beta	2.88

About MCRB

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MCRB

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MCRB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 weeks ago

-16.04%

Seres Therapeutics shares are trading lower after ... Unlock content with Pro Subscription

5 months ago

+3.83%

Seres Therapeutics shares are trading higher after the company announced that SER-155 received FDA breakthrough therapy designation for its bloodstream infection reduction.

News

1 week ago · zacks.com

Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?

Seres Therapeutics (MCRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 weeks ago · zacks.com

Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade

The mean of analysts' price targets for Seres Therapeutics (MCRB) points to a 713.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am...

4 weeks ago · seekingalpha.com

Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript

Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q1 2025 Earnings Call May 7, 2025 8:30 AM ET Company Participants Carlo Tanzi - Investor Relations Eric Shaff - President and Chief Executive Officer Marella Th...

1 month ago · zacks.com

Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround

Seres Therapeutics (MCRB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings ...

2 months ago · seekingalpha.com

Seres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call Transcript

Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Carlo Tanzi - Kendall Investor Relations Eric Shaff - President and Chief Execut...